The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
Peginterferon Alfa-2a and Ribavirin
(peg in ter FEER on AL fa too aye & rye ba VYE rin)
- Ribavirin and Peginterferon Alfa-2a
- Antihepaciviral, Nucleoside (Anti-HCV)
Peginterferon Alfa-2a: Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.
Ribavirin: Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis.
Use: Labeled Indications
Note: Not approved in the US
Hepatitis C: Combination therapy for the treatment of chronic hepatitis C (HCV) in patients without cirrhosis and patients with compensated cirrhosis; includes patients coinfected with stable HIV disease
Guideline recommendations: Peginterferon and ribavirin (without the addition of another HCV antiviral agent) is not recommended in HCV treatment guidelines (treatment naïve or treatment-experienced; with or without cirrhosis), including those co-infected with HIV. Current AASLD/IDSA recommendations do not specify a particular peginterferon (eg, 2a or 2b); however, guideline recommendations are based on clinical trials that used peginterferon alfa-2a (AASLD/IDSA 2015). Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations.
Hypersensitivity to alfa interferons, ribavirin, E. coli-derived products, polyethylene glycol (PEG), or any component of the formulation; decompensated cirrhosis; autoimmune hepatitis or history of autoimmune disease; HCV-HIV coinfection with cirrhosis and baseline Child-Pugh score ≥6 (unless score is induced by drugs known to cause indirect hyperbilirubinemia and patient is without evidence of clinical hepatic decompensation); hemoglobinopathies; history of or pre-existing severe psychiatric disorder; uncontrolled thyroid dysfunction; neonates and infants (due to benzyl alcohol component); males with a pregnant female partner; pregnancy; breast-feeding
Chronic hepatitis C (HCV) monoinfection: Note: Peginterferon alfa-2a and ribavirin (without the addition of another HCV antiviral agent) is not recommended in clinical practice guidelines for HCV patients (treatment naïve or treatment-experienced) (AASLD/IDSA 2015)
<75 kg: Peginterferon alfa-2a (SubQ): 180 mcg once weekly and ribavirin (oral) 1000 mg daily (divided into 2 doses) for 48 weeks
≥75 kg: Peginterferon alfa-2a (SubQ): 180 mcg once weekly and ribavirin (oral) 1200 mg daily (divided into 2 doses) for 48 weeks
Genotypes 2,3: Peginterferon alfa-2a (SubQ): 180 mcg once weekly and ribavirin (oral) 800 mg daily (divided into 2 doses) for 24 weeks
HIV-HCV coinfection: HCV genotypes 1,2,3,4: Peginterferon alfa-2a (SubQ): 180 mcg once weekly and ribavirin (oral) 800 mg daily (divided into 2 doses) for 48 weeks. Note: Peginterferon alfa-2a and ribavirin combination therapy is not a recommended treatment option for HCV patients (regardless of genotype) coinfected with HIV (AASLD/IDSA 2015).
Treatment futility Discontinue all treatment if HCV RNA ≥1000 units/mL at weeks 4 or 12 or detectable at week 24 (with concomitant telaprevir) or if HCV RNA ≥100 units/mL at week 12 or detectable at week 24 (with concomitant boceprevir)
Refer to adult dosing.
Dosing: Renal Impairment
Peginterferon alfa-2a: SubQ:
CrCl >20 mL/minute: No dosage adjustment necessary. Monitor closely as dose reduction may be warranted with onset of adverse events.
End-stage renal disease requiring hemodialysis: Reduce initial dosage to 135 mcg once weekly
Ribavirin: Oral: Serum creatinine >2 mg/dL (SI: 177 micromole/L) or CrCl <50 mL/minute. Use is not recommended
Dosing: Hepatic Impairment
Avoid use in decompensated hepatic disease (eg, Child-Pugh class B or C). Use is contraindicated in HCV-HIV coinfected patients with cirrhosis and baseline Child-Pugh score ≥6 (unless score is induced by drugs known to cause indirect hyperbilirubinemia and without evidence of clinical hepatic decompensation).
Peginterferon alfa-2a: SubQ: Reduce dose to 90 mcg/once weekly in the presence of progressive ALT increases greater than baseline. Therapy discontinuation may be necessary for persistently marked ALT elevations despite dose reduction and/or with accompanying elevated bilirubin or with evidence of hepatic decompensation.
Dosing: Adjustment for Toxicity
Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):
Adverse events/toxicity: For moderate-to-severe adverse reactions (clinical and/or laboratory): Reduce peginterferon alfa-2a dose to 90 to 135 mcg once weekly.
Mild depression: No dosage adjustment required; monitor closely.
Moderate depression: Decrease peginterferon alfa-2a dose to 90 to 135 mcg once weekly; monitor closely.
Severe depression: Discontinue combination therapy; obtain immediate psychiatric consultation.
Hemoglobin (patients without cardiac disease):
Hemoglobin <10 g/dL: Decrease ribavirin dose to 600 mg daily
Hemoglobin <8.5 g/dL: Discontinue ribavirin; upon resolution of decreased hemoglobin, may reinitiate ribavirin therapy at 600 mg daily with subsequent increase to 800 mg daily as tolerated; higher doses are not recommended.
Hemoglobin (patients with stable cardiac disease):
Hemoglobin decrease >2 g/dL in any 4-week period: Permanently decrease ribavirin dose to 600 mg daily.
Hemoglobin <12 g/dL after ribavirin dose is decreased for 4 weeks: Discontinue ribavirin; upon resolution of decreased hemoglobin, may reinitiate ribavirin therapy at 600 mg daily with subsequent increase to 800 mg daily as tolerated; higher doses are not recommended.
Neutrophils <0.75 x 109/L: Decrease peginterferon alfa-2a dose to 135 mcg weekly.
Neutrophils <0.5 x 109/L: Interrupt peginterferon alfa-2a therapy; may reinitiate therapy at 90 mcg weekly when ANC >1 x 109/L.
Platelet count <50 x 109/L: Decrease peginterferon alfa-2a dose to 90 mcg weekly.
Platelet count <25 x 109/L: Permanently discontinue peginterferon alfa-2a and ribavirin.
See individual agents.
Take ribavirin with food.
Pegasys RBV combination package: Store under refrigeration between 2°C and 8°C (36°F and 46°F); do not freeze. Protect from light. Do not shake. When the package is separated:
Copegus tablets: Store under refrigeration or below 30°C (86°F).
Pegasys prefilled syringes/vials: Store under refrigeration between 2°C and 8°C (36°F and 46°F); do not freeze. Protect from light. Do not shake.
Adverse reactions as reported with use of the combination product. Also see individual agents.
Central nervous system: Fatigue (40% to 49%), headache (35% to 48%), insomnia (19% to 32%), rigors (16% to 30%), irritability (15% to 28%), depression (17% to 22%), dizziness (7% to 15%)
Dermatologic: Alopecia (10% to 25%), pruritus (4% to 25%), dermatitis (1% to 16%), xeroderma (4% to 13%)
Endocrine & metabolic: Weight loss (2% to 16%)
Gastrointestinal: Nausea (24% to 29%), anorexia (20% to 27%), diarrhea (14% to 16%)
Hematologic & oncologic: Hemolytic anemia (≤14%), neutropenia (3% to 11%)
Local: Injection site reaction (10% to 28%)
Neuromuscular & skeletal: Myalgia (32% to 42%), weakness (≥1% to 26%), arthralgia (16% to 22%)
Respiratory: Cough (3% to 13%), dyspnea (3% to 13%)
Miscellaneous: Fever (37% to 41%)
1% to 10%:
Cardiovascular: Chest pain (≥1% to ≤5%), flushing (≥1% to ≤5%), hypertension (≥1% to ≤5%), palpitations (≥1% to ≤5%), peripheral edema (≥1% to ≤5%), syncope (≥1% to ≤5%), tachycardia (≥1% to ≤5%)
Central nervous system: Pain (6% to 10%), lack of concentration (2% to 10%), anxiety (8%), mood changes (<1% to 8%), malaise (3% to 6%), emotional disturbance (<1% to 5%), aggressive behavior (≥1% to ≤5%), confusion (≥1% to ≤5%), drowsiness (≥1% to ≤5%), drug abuse (≥1% to ≤5%), hyperesthesia (≥1% to ≤5%), hypoesthesia (≥1% to ≤5%), lethargy (≥1% to ≤5%), migraine (≥1% to ≤5%), myasthenia (≥1% to ≤5%), nightmares (≥1% to ≤5%), paresthesia (≥1% to ≤5%), suicidal ideation (≥1% to ≤5%), vertigo (≥1% to ≤5%), memory impairment (1% to 5%), nervousness (1% to 3%), apathy (HIV-HCV coinfection: ≥1% to ≤3%), emotional lability (HIV-HCV coinfection: ≥1% to ≤3%)
Dermatologic: Skin rash (5% to 9%), diaphoresis (2% to 5%), dermatological reaction (≥1% to ≤5%), eczema (≥1% to ≤5%), night sweats (≥1% to ≤5%), psoriasis (≥1% to ≤5%), skin photosensitivity (≥1% to ≤5%), urticaria (≥1% to ≤5%), cheilitis (HIV-HCV coinfection: ≥1% to ≤3%)
Endocrine & metabolic: Decreased libido (2% to 5%), dehydration (≥1% to ≤5%), hot flash (≥1% to ≤5%), hyperthyroidism (≥1% to ≤5%), increased thirst (≥1% to ≤5%), hypothyroidism (<1% to 4%), lactic acidosis (HIV-HCV coinfection: ≥1% to ≤3%), lipodystrophy (HIV-HCV coinfection: ≥1% to ≤3%)
Gastrointestinal: Abdominal pain (7% to 10%), nausea and vomiting (7% to 8%), xerostomia (5% to 8%), decreased appetite (≤7%), dyspepsia (2% to 6%), constipation (≥1% to ≤5%), dental bleeding (≥1% to ≤5%), dysgeusia (≥1% to ≤5%), dysphagia (≥1% to ≤5%), flatulence (≥1% to ≤5%), glossitis (≥1% to ≤5%), oral candidiasis (≥1% to ≤5%), oral mucosa ulcer (≥1% to ≤5%), sore throat (≥1% to ≤5%), stomatitis (≥1% to ≤5%)
Genitourinary: Impotence (≥1% to ≤5%), urine discoloration (HIV-HCV coinfection: ≥1% to ≤3%)
Hematologic & oncologic: Thrombocytopenia (≥1% to 8%), lymphadenopathy (≥1% to ≤5%)
Infection: Herpes virus infection (≥1% to ≤5%), influenza (HIV-HCV coinfection: ≥1% to ≤3%)
Neuromuscular & skeletal: Back pain (3% to 5%), arthritis (≥1% to ≤5%), muscle cramps (≥1% to ≤5%), musculoskeletal pain (≥1% to ≤5%), neck pain (≥1% to ≤5%), ostealgia (≥1% to ≤5%), tremor (≥1% to ≤5%)
Ophthalmic: Blurred vision (≥1% to ≤5%), eye pain (≥1% to ≤5%), uveitis (≥1% to ≤5%), xerophthalmia (≥1% to ≤5%)
Otic: Otalgia (≥1% to ≤5%), tinnitus (≥1% to ≤5%)
Respiratory: Bronchitis (≥1% to ≤5%), epistaxis (≥1% to ≤5%), flu-like symptoms (≥1% to ≤5%), nasal congestion (≥1% to ≤5%), nasopharyngitis (≥1% to ≤5%), pharyngolaryngeal pain (≥1% to ≤5%), rhinitis (≥1% to ≤5%), sinus congestion (≥1% to ≤5%), upper respiratory tract infection (≥1% to ≤5%), dyspnea on exertion (3% to 4%), pneumonia (HIV-HCV coinfection: ≥1% to ≤3%)
<1% (Limited to important or life-threatening; reported with other interferon preparations and/or ribavirin): Abdominal distention, acute psychosis, anaphylaxis, angioedema, aplastic anemia (rare), atrial fibrillation, bacterial infection (including sepsis), Bell's palsy, brain disease, bronchoconstriction, cardiac arrhythmia, cardiomyopathy, cerebral hemorrhage, cerebral ischemia, cerebrovascular hemorrhage, cholangitis, coma, congestive heart failure, corneal ulcer, deafness (rare), decreased platelet count, decreased white blood cell count, dental disorders, diabetes mellitus, endocarditis, erythema multiforme, fungal infection, gastrointestinal hemorrhage, gout, hallucination, hepatic insufficiency, hepatitis, hepatotoxicity, homicidal ideation, hyperglycemia, hypersensitivity reaction, hypertriglyceridemia, hypoglycemia, increased serum ALT, increased uric acid, interstitial nephritis, interstitial pneumonitis, ischemic colitis, ischemic heart disease, leukopenia, liver steatosis, macular edema, malignant neoplasm (hepatic), myocardial infarction, myositis, nephrotic syndrome, obtundation, optic neuritis, otitis externa, pancreatitis, pancytopenia, panic attack, papilledema, peptic ulcer, pericarditis, periodontal disease, peripheral neuropathy, pneumonitis, psychiatric signs and symptoms, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, renal failure, renal insufficiency, retinal blood vessel occlusion, retinal cotton-wool spot, retinal detachment, retinal hemorrhage, rhabdomyolysis, sarcoidosis (including exacerbation), seizure, skin infection, Stevens-Johnson syndrome, suicidal tendencies, thrombotic thrombocytopenic purpura, thyroid dysfunction, thyroiditis, tissue necrosis at injection site, toxic epidermal necrolysis, ulcerative colitis, viral infection
Use of alfa interferons has been associated with rare cases of autoimmune disease, including immune thrombocytopenia (ITP), thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and Vogt-Koyanagi-Harada syndrome
Concerns related to adverse effects:
• Bone marrow suppression: May cause bone marrow suppression, and rarely pancytopenia. Monitor blood counts closely. Use with caution if baseline ANC <1.5 x 109/L, platelets <90 x 109/L, or hemoglobin <10g/dL. Temporarily suspend or discontinue therapy for ANC <0.5 x 109/L or platelets <25 x 109/L. Dosage reduction required if ANC <0.75 x 109/L or platelets <50 x 109/L. Hemolytic anemia is a significant toxicity, usually occurring within 1-2 weeks. Suspend or discontinue ribavirin therapy for any deterioration in hemoglobin levels. Anemia may worsen underlying cardiac disease. Assess cardiac disease before initiation; avoid use of ribavirin in patients with history of significant or unstable cardiac disease. If any deterioration in cardiovascular status occurs, suspend or discontinue ribavirin therapy. Patients with renal dysfunction should be carefully assessed for development of anemia. Use caution with concomitant use of other myelosuppressive agents.
• CNS effects: May cause CNS depression (somnolence, fatigue), which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Colitis: Serious cases of ischemic/hemorrhagic colitis (some fatal) have been observed within 12 weeks of initiating alfa interferon therapy; ulcerative colitis has been reported with use as well; discontinue therapy in suspected/confirmed colitis; upon discontinuation of therapy, resolution of colitis is usually observed within 1 to 3 weeks.
• Dehydration: Maintain adequate hydration; hypotension associated with dehydration has been observed with use alfa interferons.
• Flu-like symptoms: Interferon therapy is commonly associated with flu-like symptoms, including fever; however, rule out other causes/infection with persistent fever.
• Hypersensitivity: Acute hypersensitivity (eg, anaphylaxis, angioedema, bronchoconstriction, urticaria) has been rarely observed with alfa-interferon therapy. Stevens-Johnson syndrome (SJS), erythema multiforme and toxic epidermal necrolysis (TEN) have been reported very rarely. Discontinue therapy immediately with signs of hypersensitivity and treat appropriately. Presence of transient rashes may not warrant treatment interruption in the absence of more severe reactions.
• Hypertriglyceridemia: Elevated triglyceride levels have been associated with alfa interferon therapy; monitor lipids with therapy.
• Ocular effects: May aggravate or induce vision loss/reduction, macular edema, and optic neuritis. Retinal detachment or hemorrhages, cotton wool spots, and retinal artery or vein obstruction have occurred rarely in patients using peginterferon alfa-2a. Prior to start of therapy, visual exams are recommended for all patients and periodically during therapy for patients with pre-existing ophthalmologic disorders (eg, diabetic or hypertensive retinopathy). Prompt ophthalmic evaluation is necessary if patient experiences loss of visual acuity or visual field. Discontinue therapy with new or worsening ophthalmologic disorders.
• Otic effects: Very rare cases of deafness have been reported with use.
• Pancreatitis: Pancreatitis has been reported (including fatalities). Suspend therapy for symptoms/signs suggestive of pancreatitis. Discontinue therapy with confirmed pancreatitis.
• Autoimmune disease: [Canadian Boxed Warning]: Alfa interferons (including peginterferon alfa-2a) may aggravate or cause life-threatening autoimmune disorders. Monitor patients closely and discontinue use for persistently severe or worsening symptoms. Resolution occurs in many but not all cases after discontinuation. Use is contraindicated in patients with a history of autoimmune disease; exacerbation of myositis, thyroiditis, immune thrombocytopenia (ITP), rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis has been reported with interferon therapy; consider therapy discontinuation with appearance of psoriatic lesions and sarcoidosis.
• Cardiovascular disease: Use peginterferon alfa-2a with caution in patients with cardiac disease; MI, angina, arrhythmias, heart failure, and hypertension have been associated with interferons (including peginterferon). ECG prior to initiation and during therapy is recommended. Avoid use of ribavirin in patients with unstable or severe cardiac disease within previous 6 months; anemia associated with ribavirin may worsen underlying cardiac disease. Suspend or discontinue use with worsening cardiovascular status.
• Dental disorders: Dental and periodontal disorders have been reported; xerostomia associated with therapy may also lead to detrimental effects on teeth (including loss) and oral mucous membranes. Advise patients to follow good oral hygiene (eg, brush teeth twice daily) and have regular dental exams.
• Endocrine disorders: Use with caution in patients with endocrine disorders (eg, thyroid, diabetes); hyper-/hypothyroid, diabetes mellitus and/or loss of glucose control have been observed with use of peginterferon alfa-2a. Avoid initiating therapy or discontinue existing therapy in patients whose endocrine disorder is uncontrolled. Monitor TSH and glucose; dosage adjustments of antidiabetic therapy may be necessary.
• Hepatic impairment: Use in decompensated hepatic disease or in (HIV/HCV) coinfection with cirrhosis and baseline Child-Pugh score ≥6 is contraindicated (unless score is induced by drugs known to cause indirect hyperbilirubinemia and without evidence of clinical hepatic decompensation). Use with caution in HIV/HCV coinfected patients or with mild to moderate hepatic impairment; monitor closely for hepatic decompensation. Discontinue treatment immediately with worsening hepatic function or signs/symptoms of hepatic failure. Elevated ALT may occur during therapy, including patients with a virological response; discontinue for progressive elevations in ALT despite dose reduction or if accompanied by increased bilirubin.
• Hepatitis B: Safety and efficacy have not been established in patients with hepatitis B virus infection.
• Infectious disorders: [Canadian Boxed Warning]: Alfa interferons (including peginterferon alfa-2a) may aggravate or cause fatal or life-threatening infectious disorders. Monitor patients closely and discontinue use for persistently severe or worsening symptoms. Resolution occurs in many but not all cases after discontinuation. Investigate the etiology of any persistent fever during therapy.
• Ischemic disorders: [Canadian Boxed Warning]: Alfa interferons (including peginterferon alfa-2a) may aggravate or cause life-threatening ischemic disorders. Monitor patients closely and discontinue use for persistently severe or worsening symptoms. Resolution occurs in many but not all cases after discontinuation. Cerebrovascular events (ischemic and hemorrhagic) have been observed in patients receiving alfa interferon therapy, including younger patients (ie, <45 years of age) and those without risk factors.
• Neuropsychiatric disorders: [Canadian Boxed Warning]: Alfa interferons (including peginterferon alfa-2a) may aggravate or cause fatal or life-threatening neuropsychiatric disorders. Monitor patients closely and discontinue use for persistently severe or worsening symptoms. Resolution occurs in many but not all cases after discontinuation. Use in patients with pre-existing or history of severe psychiatric disorders is contraindicated. Use with extreme caution in patients with preexisting depression; monitor all patients for evidence of depressive symptoms. Severe psychiatric adverse events (confusion, depression, suicidal behavior/ideation, aggression, mental status changes) may occur in patients with and without previous psychiatric symptoms; if severe symptoms persist, psychiatric consult should be obtained. Patients receiving alfa interferons and with a history of substance use/abuse are at increased risk of developing psychiatric disorders or experiencing exacerbation of an existing disorder; initiate therapy carefully and monitor closely during therapy and after therapy discontinuation. Early intervention for re-emergence of development of neuropsychiatric disorders and substance use is recommended.
• Renal impairment: Evaluate renal function prior to initiating therapy; use with caution in patients with renal impairment and only if considered essential. Avoid use if serum creatinine >2 mg/dL (SI: 177 micromole/L) or CrCl <50 mL/minute; monitor for signs/symptoms of toxicity (therapy discontinuation may be required if toxicity occurs).
• Respiratory disease: Avoid use in patients with chronic obstructive pulmonary disease (COPD); use caution in other pulmonary disease; dyspnea, pneumonia, pneumonitis, and pulmonary infiltrates have been reported with use. Obtain chest x-ray with onset of fever, dyspnea, cough, or other symptoms; discontinue treatment with persistent/unexplained pulmonary function impairment or pulmonary infiltrates.
• Elderly: Use with caution in elderly patients; evaluate renal function before initiating therapy.
• Organ transplant recipients: Safety and efficacy have not been established in organ transplant patients. Liver and renal graft rejection has been reported in patients receiving interferons with or without concomitant ribavirin.
• Pediatric: In combination therapy with alfa interferons, ribavirin may cause a reduction in growth velocity in pediatric patients for the length of treatment. Delay in weight and height increases have been noted in children treated with combination therapy. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. Long-term data indicate that combination therapy may inhibit growth resulting in reduced adult height. Use in patients <18 years is not recommended.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Dosage form specific issues:
• Product variability: Due to differences in dosage, patients should not change brands of interferons.
• Appropriate use: Safety and efficacy have not been established in patients who have failed other alfa interferon therapy.
Manufacturer’s labeling: Obtain pretreatment CBC, liver function tests, renal function, lipids, TSH, and electrolytes, then monitor CBC routinely throughout therapy at 2- and 4 weeks (more frequently if indicated) and other tests every 4 weeks (more frequently if indicated). Pretreatment and monthly pregnancy test (up to 6 months following therapy discontinuation) for women of childbearing age. Baseline chest x-ray, ECG, weight; patients with pre-existing cardiac abnormalities should have an ECG before and during treatment; glucose (diabetic or symptomatic patients), I & O; dental exams; neuropsychiatric monitoring; vision (pretreatment and periodic during therapy).
Serum HCV RNA levels (pretreatment, 4-, 12-, and 24 weeks after therapy initiation, 24 weeks after completion of therapy)
In addition, the following baseline values were used as entrance criteria in clinical trials:
Platelet count ≥90 x 109/L (as low as 75 x 109/L in patients with cirrhosis or transition to cirrhosis)
ANC ≥1.5 x 109/L
Serum creatinine <1.5 times ULN
TSH and T4 within normal limits or adequately controlled
CD4+ cell count ≥200 cells/microL or CD4+ cell count ≥100 cells/microL, but <200 cells/microL and HIV-1 RNA <5000 copies/mL in CHC-HIV coinfected patients
Alternate recommendations (AASLD/IDSA 2015):
Baseline (within 12 weeks prior to starting antiviral therapy): CBC, INR, hepatic function panel (albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase), calculated GFR
Baseline (at any time prior to starting antiviral therapy): HCV genotype and subtype, quantitative HCV viral load
During therapy: CBC, serum creatinine, calculated GFR, hepatic function panel (after 4 weeks of therapy and as clinically indicated); quantitative HCV viral load testing (after 4 weeks of therapy and at 12 weeks after completion of therapy). If quantitative HCV viral load is detectable at treatment week 4, repeat testing is recommended after 2 additional weeks of treatment (treatment week 6).
Use is contraindicated in females who are pregnant or males whose female partners are pregnant. Abortifacient and teratogenic effects have been reported in women receiving interferons. Negative pregnancy test is required before initiation and monthly thereafter. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If female patients or female partners of male patients become pregnant during treatment, she should be counseled about potential risks of exposure.
Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).